Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chimerix, a pharmaceutical firm that develops orally-available antiviral therapeutics, has initiated patient recruitment in a multicenter, open-label CMX001 (the CMX001-350 study) clinical study to treat life-threatening or serious conditions caused by double-stranded DNA (dsDNA) viruses.
Subscribe to our email newsletter
The study will recruit around 200 patients and will evaluate the safety, tolerability and antiviral activity of CMX001.
The primary objective of CMX001 study is to provide CMX001 to patients with immediately life-threatening or serious disease caused by any of 12 different viral infections resulting from dsDNA viruses, including herpes viruses (cytomegalovirus (CMV), adenovirus (AdV), herpes simplex virus (HSV) and Epstein Barr virus), polyoma viruses (BK virus and JC virus), and pox viruses.
Chimerix president and CEO Kenneth Moch said that data from this open-label clinical study will be a critical component of the strategy to develop CMX001 as an antiviral agent.
"We anticipate that the CMX001-350 study will provide important supportive data for our overall clinical development program," Moch said.